Alliance for Regenerative Medicine

Advocacy organization supporting advances in regenerative medicine.

Based in DC

🤖

AI Overview

With $1.5M in lobbying spend across 26 quarterly filings, Alliance for Regenerative Medicine is a significant lobbying presence. Their lobbying covers 2 issue areas. Active from 2018 to 2024.

$1.5M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$250K
2019	$150K
2020	$150K
2021	$200K
2022	$280K
2023	$360K
2024	$90K

Issues Lobbied

Health Issues Medicare/Medicaid

Lobbying Firms

Holland & Knight LLP

Lobbyists

Michael Werner Miranda Franco Ethan Jorgensen-earp Isabel Lane Marissa Serafino Jodi Chandler Paolo Mastrangelo

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid

Implementation of 21st Century Cures regenerative medicine provisions; H.R. 2430, S. 204, Trickett Wendler Right to Try Act; other FDA-related issues.

Implementation of 21st Century Cures regenerative medicine provisions; H.R. 2430, S. 204, Trickett Wendler Right to Try Act; other FDA and CMS-related issues.

Implementation of 21st Century Cures regenerative medicine provisions; regulatory and reimbursement issues.

Implementation of 21st Century Cures regenerative medicine provisions; regulatory and reimbursement issues; value-based arrangements draft legislation.

Implementation of 21st Century Cures regenerative medicine provisions; regulatory and reimbursement issues; "Value Based Payment" draft legislation.

Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; regulatory reimbursement issues; "Value Based Payment" draft legislation.

Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; regulatory reimbursement issues; "Value Based Payment" draft legislation; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act.

Patient Affordability, Value and Efficiency Act; S.2543, Prescription Drug Pricing Reduction Act of 2019; "Value Based Payment" draft legislation; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act.; Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748); Cures 2.0 legislative discussions.

Showing 8 of 18 unique descriptions from filings.